| Drug General Information |
| Drug ID |
D0X0RJ
|
| Former ID |
DNC010659
|
| Drug Name |
JNJ-26529126
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C31H33NO5
|
| Canonical SMILES |
COC1=CC2=C(C=C1)C3=C(CCO2)C4=C(C=C(C=C4)O)OC3C5=CC=C(C=<br />C5)OCCN6CCCCC6
|
| InChI |
1S/C31H33NO5/c1-34-24-10-12-27-28(20-24)36-17-13-26-25-11-7-22(33)19-29(25)37-31(30(26)27)21-5-8-23(9-6-21)35-18-16-32-14-3-2-4-15-32/h5-12,19-20,31,33H,2-4,13-18H2,1H3/t31-/m1/s1
|
| InChIKey |
BHYFKQDXXVAJEL-WJOKGBTCSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Estrogen receptor |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
Estrogen signaling pathway
|
|
Prolactin signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Endocrine and other factor-regulated calcium reabsorption
|
|
Proteoglycans in cancer
|
|
NetPath Pathway
|
FSH Signaling Pathway
|
|
EGFR1 Signaling Pathway
|
|
RANKL Signaling Pathway
|
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
|
Signaling events mediated by HDAC Class II
|
|
Plasma membrane estrogen receptor signaling
|
|
LKB1 signaling events
|
|
Regulation of Telomerase
|
|
ATF-2 transcription factor network
|
|
AP-1 transcription factor network
|
|
FOXM1 transcription factor network
|
|
Validated nuclear estrogen receptor alpha network
|
|
Signaling mediated by p38-alpha and p38-beta
|
|
FOXA1 transcription factor network
|
|
Reactome
|
Nuclear signaling by ERBB4
|
|
Nuclear Receptor transcription pathway
|
|
WikiPathways
|
Estrogen signaling pathway
|
|
Nuclear Receptors Meta-Pathway
|
|
Estrogen Receptor Pathway
|
|
Signaling by ERBB4
|
|
JAK/STAT
|
|
Integrated Pancreatic Cancer Pathway
|
|
Leptin signaling pathway
|
|
miR-targeted genes in muscle cell - TarBase
|
|
Integrated Breast Cancer Pathway
|
|
Nuclear Receptors
|
| References |
| REF 1 | J Med Chem. 2009 Dec 10;52(23):7544-69.Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms. |
|---|
